Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU.

"Conflict-of-interest disclosure: The institution of K.F. has received speaker’s fees from CSL Behring and Novo Nordisk; consultancy fees from Biogen, CSL Behring, Freeline, Novo Nordisk, Roche, and Sobi; and research support from Bayer, Pfizer, and Novo Nordisk. G.K. has received research support from Alnylam, Bayer, Opko, Pfizer, Roche, and Takeda, and consultancy fees from ASC Therapeutics, Bayer, BioMarin, CSL Behring, Novo Nordisk, Pfizer, Roche, Takeda, and UniQure. K.K. has received research funding from Bayer, CSL Behring, Swedish Orphan Biovitrum, and Shire/Takeda, and consultancy, honoraria, scientific advisory board, and/or travel expenses from Bayer, Biotest, Chugai/Roche, CSL Behring, Swedish Orphan Biovitrum and Shire/Takeda. M.C. has received research support from Bayer, Bioverativ/Sanofi, CSL Behring, Novo Nordisk, Octapharma, Pfizer, and Shire/Takeda, and speaker’s/consultancy fees from Bayer, Bioverativ/Sanofi, Biotest, CSL Behring, Grifols, LFB, Novo Nordisk, Octapharma, Pfizer, Roche, and Shire/Takeda. J.O. has received research funding from Bayer, Biotest, CSL Behring, Octapharma, Pfizer, Swedish Orphan Biovitrum, and Takeda, and consultancy, speakers bureau, honoraria, scientific advisory board, and travel expenses from Bayer, Biogen Idec, BioMarin, Biotest, Chugai, CSL Behring, Freeline, Grifols, LFB, Novo Nordisk, Octapharma, Pfizer, Roche, Sanofi, Spark Therapeutics, Swedish Orphan Biovitrum, and Takeda. A.R.C.H. has received speaker fees from Novo Nordisk and Stago. J.B. has received consultancy and/or speaker fees from Bayer, LFB, Novo Nordisk, Pfizer, Roche, Shire/Takeda, and Sobi. C.K. has received personal fees from BayerVital GmbH, CSL Behring, Novo Nordisk, Roche/Chugai, Sanofi/Sobi, and Takeda, and grants (to institution) from Bayer VitalGmbH, Biotest, CSL Behring, Intersero, Novo Nordisk, Pfizer, Sanofi/Sobi, and Takeda. The remaining authors declare no competing financial interests."

"The PedNet Registry is owned by the PedNet Haemophilia Research Foundation, a not-for-profit foundation that has received unrestricted research grants from Bayer AG, Takeda, Novo Nordisk, CSL Behring, Pfizer Inc, Biotest AG, Swedish Orphan Biovitrum AB, LFB Biotechnologies, Sanofi, and Hoffmann-La Roche. Companies supporting the PedNet Registry receive annual aggregated data on safety and efficacy of their concentrates. None of the authors received any funding for work done in relation to this manuscript."